PMID- 35874050
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220726
IS  - 2405-8440 (Print)
IS  - 2405-8440 (Electronic)
IS  - 2405-8440 (Linking)
VI  - 8
IP  - 7
DP  - 2022 Jul
TI  - Performance of the BioFire Blood Culture Identification 2 panel for the diagnosis 
      of bloodstream infections.
PG  - e09983
LID - 10.1016/j.heliyon.2022.e09983 [doi]
LID - e09983
AB  - BACKGROUND: Conventional blood cultures methods are associated with long 
      turnaround times, preventing early treatment optimization in bloodstream 
      infections. The BioFire Blood Culture Identification 2 (BCID2) Panel is a new 
      multiplex PCR applied on positive blood cultures, reducing time to pathogen 
      identification and resistant markers detection. METHODS: We conducted a 
      prospective observational study including positive blood cultures from Intensive 
      Care Units and Emergency Departments and performed BCID2 in addition to 
      conventional testing. Concordance between the two methods was assessed and BCID2 
      performance characteristics were evaluated. Resistance markers detected by BCID2 
      were confirmed by in-house PCR. Whole genome sequencing was performed in 
      discordant cases. RESULTS: Among 60 monomicrobial blood cultures, BCID2 correctly 
      identified 55/56 (91.7%) on-panel pathogens, showing an overall concordance of 
      98%. In 4/60 cases BCID2 did not detect any target and these all grew BCID2 
      off-panel bacteria. Only one discordant case was found. Sensitivity and 
      specificity for Gram-positive bacteria on monomicrobial samples were 100% (95% CI 
      85.8-100%) and 100% (95% CI 90.3-100%) respectively, while for Gram-negatives 
      100% (95% CI 87.7-100) and 96.9% (95% CI 83.8-99.9%), respectively. Among two 
      polymicrobial blood cultures, full concordance was observed in one case only. 
      BCID2 identified antimicrobial resistance genes in 6/62 samples, all confirmed by 
      in-house PCR (3 mecA/C S. epidermidis, 3 bla (CTX-M) E. coli). Estimated time to 
      results gained using BCID2 as compared to conventional testing was 9.69 h (95% 
      CI: 7.85-11.53). CONCLUSIONS: BCID2 showed good agreement with conventional 
      methods. Studies to assess its clinical impact are warranted.
CI  - (c) 2022 The Author(s).
FAU - Peri, Anna Maria
AU  - Peri AM
AD  - University of Queensland Centre for Clinical Research, Herston, Brisbane City, 
      QLD, 4029, Australia.
FAU - Bauer, Michelle J
AU  - Bauer MJ
AD  - University of Queensland Centre for Clinical Research, Herston, Brisbane City, 
      QLD, 4029, Australia.
FAU - Bergh, Haakon
AU  - Bergh H
AD  - Central Microbiology, Pathology Queensland, Royal Brisbane and Women's Hospital, 
      Herston, Brisbane City, QLD, 4029, Australia.
FAU - Butkiewicz, Dominika
AU  - Butkiewicz D
AD  - University of Queensland Centre for Clinical Research, Herston, Brisbane City, 
      QLD, 4029, Australia.
FAU - Paterson, David L
AU  - Paterson DL
AD  - University of Queensland Centre for Clinical Research, Herston, Brisbane City, 
      QLD, 4029, Australia.
AD  - Infectious Diseases Unit, Royal Brisbane and Women's Hospital, Herston, Brisbane 
      City, QLD, 4029, Australia.
FAU - Harris, Patrick Na
AU  - Harris PN
AD  - University of Queensland Centre for Clinical Research, Herston, Brisbane City, 
      QLD, 4029, Australia.
AD  - Central Microbiology, Pathology Queensland, Royal Brisbane and Women's Hospital, 
      Herston, Brisbane City, QLD, 4029, Australia.
LA  - eng
PT  - Journal Article
DEP - 20220719
PL  - England
TA  - Heliyon
JT  - Heliyon
JID - 101672560
PMC - PMC9304729
OTO - NOTNLM
OT  - Blood culture
OT  - Bloodstream infection
OT  - Molecular diagnostic techniques
OT  - Sepsis
COIS- The authors declare no conflict of interest.
EDAT- 2022/07/26 06:00
MHDA- 2022/07/26 06:01
PMCR- 2022/07/19
CRDT- 2022/07/25 03:46
PHST- 2021/12/25 00:00 [received]
PHST- 2022/03/01 00:00 [revised]
PHST- 2022/07/13 00:00 [accepted]
PHST- 2022/07/25 03:46 [entrez]
PHST- 2022/07/26 06:00 [pubmed]
PHST- 2022/07/26 06:01 [medline]
PHST- 2022/07/19 00:00 [pmc-release]
AID - S2405-8440(22)01271-3 [pii]
AID - e09983 [pii]
AID - 10.1016/j.heliyon.2022.e09983 [doi]
PST - epublish
SO  - Heliyon. 2022 Jul 19;8(7):e09983. doi: 10.1016/j.heliyon.2022.e09983. eCollection 
      2022 Jul.